An efficient step-by-step approach to select pleiotropic drug candidates against Alzheimer's disease: The discovery of neocopride
Journal of Alzheimer’s Disease · 2026-04 · 110 (4) · 1654-1666
DOI: 10.1177/13872877261424925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 13.03.2026. Verfasst von Christophe Rochais und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Caen Normandie, Normandie Univ, CERMN UR4258, Caen, France. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroprotective Agents, Drug Discovery. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Normandie Valorisation, Normandie Region-France- and the European Community.
Themen: Demenz
Abstract (Originalsprache)
Background
The selection of novel chemical entities that have a reasonable chance of showing clinical efficacy in AD patients is challenging.
Objective
The aim of this article is to outline the steps involved in a selection process that can result in the identification of potential preclinical candidates.
Methods
We used a cellular model of injured hippocampal neurons, for the validation of the association of the targets considered (acetylcholinesterase and 5-HT 4 receptor) and for the selection of multi-target ligands active in cellulo . The mechanism of the plural action of the best compound, we called neocopride, was deciphered using several in cellulo approaches. Finally, the protective effect of neocopride against short-term memory impairment was investigated in mice intoxicated with amyloid- β peptide.
Results
Our results show that neocopride displays strong protective effects against short-term memory disorders after oral administration at a dose of 3 mg/kg.
Conclusions
The findings suggest that neocopride is a promising drug candidate It is currently undergoing preclinical regulatory trials for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Caen Normandie, Normandie Univ, CERMN UR4258, Caen, France.
- Neuro-Sys, Gardanne, France.
- IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
- RONOMA Pharma, Saint Etienne du Rouvray, France.
ORCID-Profile: Sylvie Claeysen, Patrick Dallemagne
Förderung
- Normandie Valorisation
- Normandie Region-France- and the European Community
Zitieren
APA
Rochais, C., Lecoutey, C., Culley, G., Curel, T., Davis, A., Duval, E., Rouvière, L., Henriques, A., Legrand, R., Claeysen, S., Callizot, N., & Dallemagne, P. (2026). An efficient step-by-step approach to select pleiotropic drug candidates against Alzheimer's disease: The discovery of neocopride. Journal of Alzheimer’s Disease, 110(4), 1654-1666. https://doi.org/10.1177/13872877261424925
Vancouver
Rochais C, Lecoutey C, Culley G, Curel T, Davis A, Duval E, et al. An efficient step-by-step approach to select pleiotropic drug candidates against Alzheimer's disease: The discovery of neocopride. Journal of Alzheimer’s Disease. 2026;110(4):1654-1666. doi:10.1177/13872877261424925
BibTeX
@article{Rochais2026,
author = {Rochais, Christophe and Lecoutey, Cédric and Culley, Georgia and Curel, Thomas and Davis, Audrey and Duval, Emilie and Rouvière, Laura and Henriques, Alexandre and Legrand, Romain and Claeysen, Sylvie and Callizot, Noëlle and Dallemagne, Patrick},
title = {An efficient step-by-step approach to select pleiotropic drug candidates against Alzheimer's disease: The discovery of neocopride},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
volume = {110},
number = {4},
pages = {1654--1666},
doi = {10.1177/13872877261424925}
}
EUVIMED